Search

Introduction: Evidence indicates cardiovascular risk may start early in life. Data on specific risk factors including lipids in childhood and adolescence are scant. We investigate lipid profiles in overweight/obese patients. Methods: Data on pediatric ICLDC patients (N=11,116) with complete lipid profile (2009-2019) were extracted. Overweight/obese category (BMI ≥ 85th percentile) was divided into: prediabetes (Pre-Dia), type1 (T1DM), type 2 (T2DM) and normoglycemic (NGT) groups. Lipid percentiles were calculated for all lipids; distribution curves were plotted on R and statistical analyses performed on SPSS24. Results: Patients (n=4659) included: Pre-Dia (24%), diabetes (T1DM 6%, T2DM 2%) and NGT (68%). Total cholesterol (TC), LDL and non-HDL were significantly increased (p≤0.001) and HDL was significantly decreased (p≤0.001) in diabetes groups compared to NGT; except TC in NGT vs. Pre-Dia. Different trends arose in between diabetes groups whereby TC, LDL and non-HDL were significantly increased (p≤0.001) while HDL was significantly decreased (p≤0.001); except for LDL, non-HDL and TC in T1DM vs. T2DM, non-HDL in Pre-Dia vs. T1DM and TC in Pre-Dia vs. T2DM. Conclusion: Even at an early age, significant increases in TC, LDL and non-HDL, accompanied by decreases in HDL, were observed in patients with type 1, type 2 diabetes and prediabetes groups. Early intervention may need to be considered. Disclosure T. Ali: None. S. Radha: None. R. Helal: None. E. Fojas: None. S. I. El-refer: None. H. M. Sabbour: Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk, Novo Nordisk. N. Lessan: None.

Background: Liraglutide 3 mg was approved in the UAE for the treatment of obesity in residents with BMI >30 kg/m2 or BMI >27 kg/m2 with obesity-related complications and clinical use started in January 2017 at the Imperial College London Diabetes Centre (ICLDC). The proportions of participants achieving weight loss of ≥5%, ≥10% and ≥15% at 16 weeks were 60%, 23% and 6%. Methods: Retrospective review of clinical data from a cohort of patients treated at ICLDC in Abu Dhabi and Al Ain, UAE. Inclusion criteria were treatment with Liraglutide 3 mg for weight loss and follow-up of ≥ 56 weeks (4 weeks dose escalation plus 52 weeks treatment). 93% of participants were Emirati. Results: 322 individuals were included. Median follow-up was 485 (433-551) days and treatment was stopped in 75 individuals before end of follow-up. 91 received treatment ≥ 365 days, and 27 had no gaps in treatment > 30 days during follow-up, with a median of 265 (151-381) days of treatment. Eight participants had T2DM and 190 had IFG or IGT. 28 had prior history of bariatric surgery (18 sleeve, 8 RYGB, 2 other). Intentional to treat analysis suggested that after a year, ≥ 5% weight loss was achieved in 51%, ≥ 10% in 25% and ≥ 15% in 9%. Per protocol analysis suggested completing 1 year of treatment resulted in ≥ 5% in 83.5%, ≥ 10% in 52.7% and ≥ 15% in 22.2% of patients. Conclusion: Weight loss continued between 16 and 56 weeks, but gaps in treatment may have impaired effectiveness. Disclosure A.J. Buckley: None. M. Suliman: None. A. Al Tikriti: None. N. Lessan: None. C. le Roux: Advisory Panel; Self; GI Dynamics, Inc., Herbalife International of America, Inc., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novo Nordisk A/S. Speaker's Bureau; Self; Merck Sharp & Dohme Corp. T.M. Tan: Other Relationship; Self; Novo Nordisk A/S. M.T. Barakat: None.